BioSpace News Archive

Job Trends

Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx®-Melanoma test with clinicopathologic features to improve prediction of patients’ risk of melanoma recurrence.

October 31, 2019
·
7 min read
Policy

Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

Highly statistically significant activity relative to vehicle across every assessed symptom and sign observed in allergen chamber clinical trial

October 31, 2019
·
10 min read
Drug Development

U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

Successful conclusion of an End of Phase II meeting with the FDA

October 31, 2019
·
6 min read
Business

Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

Obalon Therapeutics, Inc. announces that it plans to release its third quarter 2019 financial results before the market opens on Friday, November 8, 2019 and hold a conference call at 9:00 AM Eastern Time to discuss the Company’s financial results and provide a business update.

October 31, 2019
·
1 min read
Pharm Country

Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)

The government of the Democratic Republic of the Congo (DRC) has decided to use the investigational Ebola vaccine regimen currently being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson as part of an expanded public health initiative to help contain the country’s Ebola outbreak

October 31, 2019
·
13 min read
Business

Indivior 2019 Third Quarter and Nine Months Results Now Available; Conference Call With Leadership Today

Indivior PLC (LON: INDV) today announced that its Q3/YTD 2019 results press release and investor supplement are now available via the London Stock Exchange’s Regulatory News Service (RNS) and on the “Investors” section of the company’s website at www.indivior.com.

October 31, 2019
·
1 min read
Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

October 31, 2019
·
4 min read
Policy

Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy

October 31, 2019
·
7 min read
Business

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis

October 31, 2019
·
11 min read
Business

Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update

Navidea Biopharmaceuticals, Inc. announced it will host a conference call and webcast on Thursday, November 7, 2019 at 5:00 p.m. to discuss developments for the third quarter of 2019..

October 31, 2019
·
4 min read